Compare abrdn Income Credit Strategies Fund (ACP) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? abrdn Income Credit Strategies Fund trades at $5.14 (market cap $641.16M), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.85 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 14.7× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| ACP | BIO | |
|---|---|---|
Market Cap | $641.16M | $9.43B |
Sector | Financials | Health |
52-Week High | $5.98 | $356.25 |
52-Week Low | $5.01 | $241.71 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $9.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a bearish technical signal from moving averages. The stock shows a low P/E of 7.74 and P/B of 0.9, indicating potential undervaluation, while a high net income margin of 95.31% and consistent dividend payments highlight financial strength. Recent news confirms dividend declarations for 2026.
The outlook is mixed; attractive valuation and dividends offer opportunity, but volatile revenue, an unsustainable distribution rate flagged by analysts, and high leverage pose significant risks. Investor sentiment is cautious due to these fundamental concerns.
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
